Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Maximum Strength Cold & Flu Relief Direct Dose Blackcurrant
0407010ABBCABAB
|
Boots (Paracetamol/phenylephrine hydrochloride) | Paracetamol and phenylephrine hydrochloride | Central Nervous System | No data available |
|
Maximum Strength Cold & Flu Relief Direct Dose Lemon pdr
0407010ABBCAAAB
|
Boots (Paracetamol/phenylephrine hydrochloride) | Paracetamol and phenylephrine hydrochloride | Central Nervous System | No data available |
|
Maxolon 10mg/2ml solution for injection ampoules
0406000P0BBADAB
|
Maxolon | Metoclopramide hydrochloride | Central Nervous System | No data available |
|
Maxolon 5mg tablets
0406000P0BBAIAP
|
Maxolon | Metoclopramide hydrochloride | Central Nervous System | No data available |
|
Maxolon 5mg/5ml syrup
0406000P0BBABAD
|
Maxolon | Metoclopramide hydrochloride | Central Nervous System | No data available |
|
Maxolon High Dose 100mg/20ml solution for injection ampoules
0406000P0BBAGAF
|
Maxolon | Metoclopramide hydrochloride | Central Nervous System | No data available |
|
Maxolon Paediatric 5mg/5ml liquid
0406000P0BBACAD
|
Maxolon | Metoclopramide hydrochloride | Central Nervous System | No data available |
|
Maxolon SR 15mg capsules
0406000P0BBAHAJ
|
Maxolon | Metoclopramide hydrochloride | Central Nervous System | No data available |
|
Mazindol 1mg tablets
0405020N0AAABAB
|
Mazindol | Mazindol | Central Nervous System | No data available |
|
Mazindol 2mg tablets
0405020N0AAAAAA
|
Mazindol | Mazindol | Central Nervous System | No data available |
|
Meclozine 12.5mg pastilles sugar free
0406000N0AAACAC
|
Meclozine hydrochloride | Meclozine hydrochloride | Central Nervous System | No data available |
|
Meclozine 12.5mg tablets
0406000N0AAAAAA
|
Meclozine hydrochloride | Meclozine hydrochloride | Central Nervous System | No data available |
|
Medinol For Children 120mg/5ml oral suspension
0407010H0B4ADAW
|
Medinol | Paracetamol | Central Nervous System | No data available |
|
Medinol Over 6 paracetamol 250mg/5ml oral suspension
0407010H0B4ABBG
|
Medinol | Paracetamol | Central Nervous System | No data available |
|
Medinol Paediatric paracetamol 120mg/5ml oral suspension
0407010H0B4AAAW
|
Medinol | Paracetamol | Central Nervous System | No data available |
|
Medinol Under 6 paracetamol 120mg/5ml oral suspension
0407010H0B4ACAW
|
Medinol | Paracetamol | Central Nervous System | No data available |
|
Medised For Children oral solution
0407010X0BDABBM
|
Medised | Paracetamol combined preparations | Central Nervous System | No data available |
|
Medocodene 30mg/500mg capsules
0407010F0BRAAAD
|
Medocodene | Co-codamol (Codeine phosphate/paracetamol) | Central Nervous System | No data available |
|
Medocodene 30mg/500mg effervescent tablets
0407010F0BRABAF
|
Medocodene | Co-codamol (Codeine phosphate/paracetamol) | Central Nervous System | No data available |
|
Melatonin 15mg/5ml oral suspension
0401010ADAACKCK
|
Melatonin | Melatonin | Central Nervous System | No data available |
|
Melatonin 20mg capsules
0401010ADAABMBM
|
Melatonin | Melatonin | Central Nervous System | No data available |
|
Melatonin 3mg lozenges sugar free
0401010ADAABIBI
|
Melatonin | Melatonin | Central Nervous System | No data available |
|
Melatonin 3mg orodispersible tablets
0401010ADAACCCC
|
Melatonin | Melatonin | Central Nervous System | No data available |
|
Melatonin 4mg/5ml oral solution
0401010ADAABGBG
|
Melatonin | Melatonin | Central Nervous System | No data available |
|
Melatonin 500microgram capsules
0401010ADAAACAC
|
Melatonin | Melatonin | Central Nervous System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.